Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting

You may also be interested in...

Chart: Antithrombotics: In A Crowded Field Of Candidates, Does Being First Matter?

The cresting wave of novel antithrombotic NDAs could mean 2010 will be a difficult year for FDA's Division of Cardiovascular and Renal Products, as the products have massive applications and tricky risk-benefit evaluations.

Boehringer-Ingelheim Now RE-LYing On Pradaxa Approval In Stroke Prevention

As Boehringer-Ingelheim scrambles to file its oral anticoagulant Pradaxa with FDA, likely for stroke prevention in patients with atrial fibrillation, physicians already have started weighing the pros and cons of the drug's two possible doses

Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin

The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts